This suggested that OSGIN-1 upregulation in ferroptosis is mediated by the NFE2L2 transcription factor, a conclusion that was supported by a ChIP assay that showed direct binding of NFE2L2 to the OSGIN-1 promoter following treatment with ferroptosis inducers, but not the doxorubicin tumor-suppressive positive control. The gene discussed is OSGIN1; the disease is neoplasm.